These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 22958421

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. In vitro prevention of Pseudomonas aeruginosa early biofilm formation with antibiotics used in cystic fibrosis patients.
    Fernández-Olmos A, García-Castillo M, Maiz L, Lamas A, Baquero F, Cantón R.
    Int J Antimicrob Agents; 2012 Aug; 40(2):173-6. PubMed ID: 22727530
    [Abstract] [Full Text] [Related]

  • 3. Use of Calgary and Microfluidic BioFlux Systems To Test the Activity of Fosfomycin and Tobramycin Alone and in Combination against Cystic Fibrosis Pseudomonas aeruginosa Biofilms.
    Díez-Aguilar M, Morosini MI, Köksal E, Oliver A, Ekkelenkamp M, Cantón R.
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084746
    [Abstract] [Full Text] [Related]

  • 4. Advances toward the elucidation of hypertonic saline effects on Pseudomonas aeruginosa from cystic fibrosis patients.
    Michon AL, Jumas-Bilak E, Chiron R, Lamy B, Marchandin H.
    PLoS One; 2014 Jan; 9(2):e90164. PubMed ID: 24587256
    [Abstract] [Full Text] [Related]

  • 5. Activity of Antibiotics against Pseudomonas aeruginosa in an In Vitro Model of Biofilms in the Context of Cystic Fibrosis: Influence of the Culture Medium.
    Diaz Iglesias Y, Van Bambeke F.
    Antimicrob Agents Chemother; 2020 Mar 24; 64(4):. PubMed ID: 32015047
    [Abstract] [Full Text] [Related]

  • 6. A Low-Molecular-Weight Alginate Oligosaccharide Disrupts Pseudomonal Microcolony Formation and Enhances Antibiotic Effectiveness.
    Pritchard MF, Powell LC, Jack AA, Powell K, Beck K, Florance H, Forton J, Rye PD, Dessen A, Hill KE, Thomas DW.
    Antimicrob Agents Chemother; 2017 Sep 24; 61(9):. PubMed ID: 28630204
    [Abstract] [Full Text] [Related]

  • 7. In vitro evaluation of tobramycin and aztreonam versus Pseudomonas aeruginosa biofilms on cystic fibrosis-derived human airway epithelial cells.
    Yu Q, Griffin EF, Moreau-Marquis S, Schwartzman JD, Stanton BA, O'Toole GA.
    J Antimicrob Chemother; 2012 Nov 24; 67(11):2673-81. PubMed ID: 22843834
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of the combination of tobramycin and a macrolide in an in vitro Pseudomonas aeruginosa mature biofilm model.
    Tré-Hardy M, Nagant C, El Manssouri N, Vanderbist F, Traore H, Vaneechoutte M, Dehaye JP.
    Antimicrob Agents Chemother; 2010 Oct 24; 54(10):4409-15. PubMed ID: 20696878
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions.
    McCaughey G, McKevitt M, Elborn JS, Tunney MM.
    J Cyst Fibros; 2012 May 24; 11(3):163-72. PubMed ID: 22138067
    [Abstract] [Full Text] [Related]

  • 11. In vitro activity of clarithromycin in combination with other antimicrobial agents against biofilm-forming Pseudomonas aeruginosa strains.
    Kádár B, Szász M, Kristóf K, Pesti N, Krizsán G, Szentandrássy J, Rókusz L, Nagy K, Szabó D.
    Acta Microbiol Immunol Hung; 2010 Sep 24; 57(3):235-45. PubMed ID: 20870595
    [Abstract] [Full Text] [Related]

  • 12. Antimicrobial activity of tobramycin against respiratory cystic fibrosis Pseudomonas aeruginosa isolates from Bulgaria.
    Strateva T, Petrova G, Mitov I.
    J Chemother; 2010 Dec 24; 22(6):378-83. PubMed ID: 21303744
    [Abstract] [Full Text] [Related]

  • 13. Characterization by phenotypic and genotypic methods of metallo-β-lactamase-producing Pseudomonas aeruginosa isolated from patients with cystic fibrosis.
    Li Y, Zhang X, Wang C, Hu Y, Niu X, Pei D, He Z, Bi Y.
    Mol Med Rep; 2015 Jan 24; 11(1):494-8. PubMed ID: 25323940
    [Abstract] [Full Text] [Related]

  • 14. Airway biofilms: implications for pathogenesis and therapy of respiratory tract infections.
    Kobayashi H.
    Treat Respir Med; 2005 Jan 24; 4(4):241-53. PubMed ID: 16086598
    [Abstract] [Full Text] [Related]

  • 15. Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis.
    Moskowitz SM, Foster JM, Emerson J, Burns JL.
    J Clin Microbiol; 2004 May 24; 42(5):1915-22. PubMed ID: 15131149
    [Abstract] [Full Text] [Related]

  • 16. Effect of pH on the antimicrobial susceptibility of planktonic and biofilm-grown clinical Pseudomonas aeruginosa isolates.
    Moriarty TF, Elborn JS, Tunney MM.
    Br J Biomed Sci; 2007 May 24; 64(3):101-4. PubMed ID: 17910277
    [Abstract] [Full Text] [Related]

  • 17. Biofilm production using distinct media and antimicrobial susceptibility profile of Pseudomonas aeruginosa.
    Perez LR, Barth AL.
    Braz J Infect Dis; 2011 May 24; 15(4):301-4. PubMed ID: 21860998
    [Abstract] [Full Text] [Related]

  • 18. Effect of iron chelation on anti-pseudomonal activity of doxycycline.
    Faure ME, Cilibrizzi A, Abbate V, Bruce KD, Hider RC.
    Int J Antimicrob Agents; 2021 Dec 24; 58(6):106438. PubMed ID: 34547423
    [Abstract] [Full Text] [Related]

  • 19. Use of artificial sputum medium to test antibiotic efficacy against Pseudomonas aeruginosa in conditions more relevant to the cystic fibrosis lung.
    Kirchner S, Fothergill JL, Wright EA, James CE, Mowat E, Winstanley C.
    J Vis Exp; 2012 Jun 05; (64):e3857. PubMed ID: 22711026
    [Abstract] [Full Text] [Related]

  • 20. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
    Smith S, Waters V, Jahnke N, Ratjen F.
    Cochrane Database Syst Rev; 2020 Jun 10; 6(6):CD009528. PubMed ID: 32520436
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.